Skip to content
Oncology Research Hub

Detroit, Michigan

Cancer clinical trials in Detroit, MI

164 cancer studies are recruiting participants at sites in Detroit as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Detroit at a glance

  • 164 studies are recruiting at a site in Detroit.
  • By phase: Phase 1 (20), Phase 1/2 (35), Phase 2 (25), Phase 2/3 (5), Phase 3 (61), No phase (10), Observational (8). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (99), university, hospital or other (50), government (15).
  • By research area: Breast Cancer (47), Lung Cancer (45), Lymphoma (32), Prostate Cancer (18), Pancreatic Cancer (17), Melanoma (5).
  • Most recent update to one of these records: November 16, 2026.

Breast cancer studies recruiting in Detroit

Basic details from each study's public record (the 30 most recently updated of 164). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Henry Ford Hospital
    Registry record
    NCT05894239 · updated
  2. A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    Barbara Ann Karmanos Cancer Center
    Registry record
    NCT07488676 · updated
  3. S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Henry Ford Hospital · Wayne State University/Karmanos Cancer Institute
    Registry record
    NCT03418961 · updated
  4. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Henry Ford Health Saint John Hospital · Henry Ford Hospital · Wayne State University/Karmanos Cancer Institute
    Registry record
    NCT06058377 · updated
  5. A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study sites
    Brigitte Harris Cancer Pavilion BHCP · Karmanos Cancer Institute
    Registry record
    NCT06827236 · updated
  6. A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study site
    Karmanos Cancer Institute
    Registry record
    NCT07503808 · updated
  7. S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    Ascension Saint John Hospital
    Registry record
    NCT03723928 · updated
  8. The Vanguard Study: Testing a New Way to Screen for Cancer

    • No phase
    • Ages 45 to 75
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Henry Ford Hospital · Henry Ford Medical Center - Detroit Northwest
    Registry record
    NCT06995898 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Detroit, MI on ClinicalTrials.gov.

Lung cancer studies recruiting in Detroit

  1. A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study site
    Henry Ford Health System
    Registry record
    NCT07111520 · updated
  2. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Henry Ford Health Saint John Hospital · Henry Ford Hospital
    Registry record
    NCT04267848 · updated
  3. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Henry Ford Health Saint John Hospital · Henry Ford Hospital
    Registry record
    NCT06498635 · updated
  4. Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT07291037 · updated
  5. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Inhibrx Biosciences, Inc
    Study site
    Henry Ford Cancer Institute
    Registry record
    NCT04198766 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Detroit, MI on ClinicalTrials.gov.

Prostate cancer studies recruiting in Detroit

  1. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Henry Ford Health Saint John Hospital · Henry Ford Hospital
    Registry record
    NCT03866382 · updated
  2. Sacral Neuromodulation for Male Overactive Bladder (MOAB)

    • No phase
    • Ages 18 and older
    • Male participants
    Sponsor
    Axonics, Inc.
    Study site
    Wayne State University
    Registry record
    NCT06511141 · updated
  3. A Comparison of Radical Prostatectomy and Precision Prostatectomy in Low- and Intermediate-risk Prostate Cancers.

    • No phase
    • All ages
    • Male participants
    Sponsor
    Henry Ford Health System
    Study site
    Henry Ford Health
    Registry record
    NCT07348367 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Detroit, MI on ClinicalTrials.gov.

Melanoma studies recruiting in Detroit

  1. A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.

    • Phase 1
    • Ages 18 and older
    • Female participants
    Sponsor
    Outpace Bio, Inc.
    Study site
    Karmanos Cancer Institute
    Registry record
    NCT07664735 · updated
  2. A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    Henry Ford Cancer Institute/Henry Ford Health System
    Registry record
    NCT06246916 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Detroit, MI on ClinicalTrials.gov.

Lymphoma studies recruiting in Detroit

  1. Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eastern Cooperative Oncology Group
    Study site
    Wayne State University/Karmanos Cancer Institute
    Registry record
    NCT06724237 · updated
  2. A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Nurix Therapeutics, Inc.
    Study site
    Karmanos Cancer Center
    Registry record
    NCT07221500 · updated
  3. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Karmanos Cancer Institute ( Site 0174)
    Registry record
    NCT06717347 · updated
  4. Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Henry Ford Health Saint John Hospital
    Registry record
    NCT03739814 · updated
  5. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Henry Ford Health Saint John Hospital · Henry Ford Hospital
    Registry record
    NCT04269902 · updated
  6. Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Henry Ford Hospital · Wayne State University/Karmanos Cancer Institute
    Registry record
    NCT04840602 · updated
  7. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Children's Hospital of Michigan · Henry Ford Hospital · Wayne State University/Karmanos Cancer Institute
    Registry record
    NCT05675410 · updated
  8. A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    Karmanos Cancer Institute
    Registry record
    NCT06091254 · updated
  9. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Henry Ford Hospital · Wayne State University/Karmanos Cancer Institute
    Registry record
    NCT06337318 · updated
  10. A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    Nuvalent Inc.
    Study site
    Henry Ford Cancer Institute
    Registry record
    NCT05384626 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Detroit, MI on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Detroit

  1. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study site
    Investigative Site US010
    Registry record
    NCT07522073 · updated
  2. APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Henry Ford Health Saint John Hospital
    Registry record
    NCT04858334 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Detroit, MI on ClinicalTrials.gov.

Ask about studies near Detroit

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Michigan

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call